Better Therapeutics Receives FDA Authorization for AspyreRx™ to Treat Adults with Type 2 Diabetes
AspyreRx was reviewed through the FDA’s De Novo pathway and its authorization creates a new class of diabetes digital behavioral therapeutic devices.
- AspyreRx was reviewed through the FDA’s De Novo pathway and its authorization creates a new class of diabetes digital behavioral therapeutic devices.
- “This De Novo authorization also provides a foundation for potential future growth opportunities.
- AspyreRx is designed to address these barriers, leveraging technology to deliver an evidence-based therapeutic intervention to patients.
- Investors and the general public may access a live webcast of the call by visiting https://edge.media-server.com/mmc/p/adggoags